Advertisement
Screener

PRECIGEN, INC. (PGEN) Investment Income, Nonoperating

PRECIGEN, INC. Investment Income, Nonoperating

PRECIGEN, INC. (PGEN) reported Investment Income, Nonoperating of $366.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Income Statement › Other Income

us-gaap:InvestmentIncomeNonoperating · last filed 2026-08-04

  • PRECIGEN, INC. investment income, nonoperating for the quarter ending 2026-06-30 was $366.00K, a 47.41% decline year-over-year.
  • PRECIGEN, INC. investment income, nonoperating for the quarter ending 2026-03-31 was $683.00K, a 25.60% decline year-over-year.
  • PRECIGEN, INC. investment income, nonoperating for the quarter ending 2025-06-30 was $696.00K.
  • PRECIGEN, INC. investment income, nonoperating for the quarter ending 2025-03-31 was $918.00K.
  • PRECIGEN, INC. investment income, nonoperating for fiscal 2025 was $3.21M, a 126.73% increase from fiscal 2024.
  • PRECIGEN, INC. investment income, nonoperating for fiscal 2024 was $1.42M, a 56.19% decline from fiscal 2023.
  • PRECIGEN, INC. investment income, nonoperating for fiscal 2023 was $3.24M.
  • PRECIGEN, INC. investment income, nonoperating for fiscal 2018 was $19.08M, a 2.06% decline from fiscal 2017.
Period endInvestment Income, Nonoperating 3 monthInvestment Income, Nonoperating 3 month as first filedInvestment Income, Nonoperating 6 monthInvestment Income, Nonoperating 6 month as first filedInvestment Income, Nonoperating 9 monthInvestment Income, Nonoperating 12 month
2026-06-30$366.00K
10-Q · filed 2026-08-04
$1.05M
10-Q · filed 2026-08-04
2026-03-31$683.00K
10-Q · filed 2026-05-13
2025-12-31$3.21M
10-K · filed 2026-03-25
2025-06-30$696.00K
10-Q · filed 2026-08-04
$1.61M
10-Q · filed 2026-08-04
2025-03-31$918.00K
10-Q · filed 2026-05-13
2024-12-31$1.42M
10-K · filed 2026-03-25
2023-12-31$3.24M
10-K · filed 2026-03-25
2019-09-30$885.00K
10-Q · filed 2019-11-12
$1.92M
derived: sum of 2 quarters · filed 2019-11-12
$3.28M
10-Q · filed 2019-11-12
$5.04M
derived: sum of 4 quarters · filed 2019-11-12
2019-06-30$1.03M
10-Q · filed 2019-08-09
$2.40M
10-Q · filed 2019-08-09
$4.16M
derived: sum of 3 quarters · filed 2019-08-09
$10.26M
derived: sum of 4 quarters · filed 2019-11-12
2019-03-31$1.36M
10-Q · filed 2019-05-09
$3.13M
derived: sum of 2 quarters · filed 2019-05-09
$9.23M
derived: sum of 3 quarters · filed 2019-11-12
$14.98M
derived: sum of 4 quarters · filed 2019-11-12
2018-12-31$1.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$7.87M
derived: sum of 2 quarters · filed 2019-11-12
$13.61M
derived: sum of 3 quarters · filed 2019-11-12
$19.08M
10-K · filed 2019-03-01
2018-09-30$6.11M
10-Q · filed 2019-11-12
$11.85M
derived: sum of 2 quarters · filed 2019-11-12
$17.32M
10-Q · filed 2019-11-12
$22.37M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$5.75M
10-Q · filed 2019-08-09
$11.22M
10-Q · filed 2019-08-09
$16.26M
derived: sum of 3 quarters · filed 2019-08-09
$21.33M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$5.47M
10-Q · filed 2019-05-09
$10.52M
derived: sum of 2 quarters · filed 2019-05-09
$15.59M
derived: sum of 3 quarters · filed 2019-05-09
$20.33M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$5.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$10.12M
derived: sum of 2 quarters · filed 2019-03-01
$14.86M
derived: sum of 3 quarters · filed 2019-03-01
$19.48M
10-K · filed 2019-03-01
2017-09-30$5.07M
10-Q · filed 2018-11-08
$9.81M
derived: sum of 2 quarters · filed 2018-11-08
$14.44M
10-Q · filed 2018-11-08
$18.81M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$4.74M
10-Q · filed 2018-08-13
$9.37M
10-Q · filed 2018-08-13
$13.74M
derived: sum of 3 quarters · filed 2019-03-01
$18.23M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$4.62M
10-Q/A · filed 2018-08-13
$9.00M
derived: sum of 2 quarters · filed 2019-03-01
$13.49M
derived: sum of 3 quarters · filed 2019-03-01
$14.20M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31$4.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$8.87M
derived: sum of 2 quarters · filed 2019-03-01
$9.58M
derived: sum of 3 quarters · filed 2019-03-01
$10.19M
10-K · filed 2019-03-01
2016-09-30$4.49M
10-Q · filed 2017-11-09
$5.21M
derived: sum of 2 quarters · filed 2017-11-09
$5.82M
10-Q · filed 2017-11-09
$6.49M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30$713.00K
10-Q · filed 2017-08-09
$1.32M
10-Q · filed 2017-08-09
$2.00M
derived: sum of 3 quarters · filed 2018-03-01
$2.56M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31$610.00K
10-Q · filed 2017-05-10
$1.28M
derived: sum of 2 quarters · filed 2018-03-01
$1.85M
derived: sum of 3 quarters · filed 2018-03-01
$2.19M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31$673.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
$1.24M
derived: sum of 2 quarters · filed 2018-03-01
$1.58M
derived: sum of 3 quarters · filed 2018-03-01
$1.88M
10-K · filed 2018-03-01
2015-09-30$567.00K
10-Q · filed 2016-11-09
$911.00K
derived: sum of 2 quarters · filed 2016-11-09
$1.21M
10-Q · filed 2016-11-09
$1.67M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$344.00K
10-Q · filed 2016-08-09
$644.00K
10-Q · filed 2016-08-09
$1.10M
derived: sum of 3 quarters · filed 2017-03-01
$1.30M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$300.00K
10-Q · filed 2016-05-10
$757.00K
derived: sum of 2 quarters · filed 2017-03-01
$959.00K
derived: sum of 3 quarters · filed 2017-03-01
$1.07M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$457.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$659.00K
derived: sum of 2 quarters · filed 2017-03-01
$769.00K
derived: sum of 3 quarters · filed 2017-03-01
$806.00K
10-K · filed 2017-03-01
2014-09-30$202.00K
10-Q · filed 2015-11-09
$312.00K
derived: sum of 2 quarters · filed 2015-11-09
$349.00K
10-Q · filed 2015-11-09
$508.00K
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$110.00K
10-Q · filed 2015-08-10
$198.00K
10-Q · filed 2015-08-10
$306.00K
derived: sum of 3 quarters · filed 2016-02-29
$344.00K
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$88.00K
10-Q · filed 2015-05-11
$196.00K
derived: sum of 2 quarters · filed 2016-02-29
$234.00K
derived: sum of 3 quarters · filed 2016-02-29
$249.00K
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$108.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$146.00K
derived: sum of 2 quarters · filed 2016-02-29
$161.00K
derived: sum of 3 quarters · filed 2016-02-29
$166.00K
10-K · filed 2016-02-29
2013-09-30$38.00K
10-Q · filed 2014-11-13
$53.00K
derived: sum of 2 quarters · filed 2014-08-14
$58.00K
10-Q · filed 2014-11-13
$60.00K
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30$15.00K
10-Q · filed 2014-08-14
$66.00K
10-Q/A · filed 2013-10-21
$20.00K
10-Q · filed 2014-08-14
$71.00K
10-Q/A · filed 2013-10-21
$22.00K
derived: sum of 3 quarters · filed 2015-03-02
$23.00K
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31$5.00K
10-Q · filed 2014-05-09
$7.00K
derived: sum of 2 quarters · filed 2015-03-02
$8.00K
derived: sum of 3 quarters · filed 2015-03-02
$9.00K
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31$2.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$3.00K
derived: sum of 2 quarters · filed 2015-03-02
$4.00K
derived: sum of 3 quarters · filed 2015-03-02
$5.00K
10-K · filed 2015-03-02
2012-09-30$1.00K
10-Q · filed 2013-11-07
$2.00K
derived: sum of 2 quarters · filed 2013-11-07
$3.00K
10-Q · filed 2013-11-07
2012-06-30$1.00K
10-Q/A · filed 2013-10-21
$2.00K
10-Q/A · filed 2013-10-21
2011-12-31$6.00K
10-K · filed 2014-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67